Trial Profile

Safety and Pharmacokinetics of Ppi-461, a Potent New Hepatitis C Virus (Hcv) Ns5a Inhibitor with Pan-Genotype Activity

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Feb 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PPI 461 (Primary)
Indications Hepatitis C
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

27 Oct 2010 Results from this trial will be presented at the American Association for the Study of Liver Diseases (AASLD) according to a Presidio Pharmaceuticals media release.
14 Jul 2010 Status changed from recruiting to completed, according to a Presidio Pharmaceuticals media release.
14 Jul 2010 Results reported in a Presidio Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com